Who Owns Organogenesis Company?

Organogenesis Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns Organogenesis Holdings Inc.?

Understanding Organogenesis Holdings Inc.'s ownership is key to its strategy and accountability. In November 2024, a private placement of Series A Convertible Preferred Stock with Avista Healthcare Partners affiliates significantly altered its ownership structure.

Organogenesis, a leader in regenerative medicine, focuses on advanced wound care and surgical markets. Its commitment to healing through innovative products, like those discussed in the Organogenesis PESTEL Analysis, underpins its market presence.

The company's net revenue was $482.0 million in 2024. This financial performance highlights its substantial role in the regenerative medicine sector.

Key stakeholders include founders, institutional investors, and public shareholders. Examining these groups reveals the evolving ownership of Organogenesis Holdings Inc.

While the exact equity distribution at Organogenesis Holdings Inc.'s inception isn't detailed in recent public records, the influence of its founders and early backers is clear. Alan A. Ades, a former Chair of the Board until April 2023, and his family have consistently held a significant ownership stake. His son, Robert Ades, also contributes to the company's direction as a board member, underscoring the family's sustained involvement.

Founding Influence

The Ades family's long-standing presence and significant ownership highlight their foundational role in the company's development and ongoing strategy.

Early Financial Backing

Initial investment from entities like Avista Capital Partners IV, L.P. was crucial for growth, providing capital and strategic input.

Board Representation

Agreements with early investors, such as the right to appoint a board director, demonstrate how initial capital infusions shaped governance.

Family Legacy

The continued involvement of Robert Ades on the board signifies the enduring family commitment to the company's vision.

Ownership Structure Evolution

Early ownership structures often lay the groundwork for future capital raises and public offerings, influencing who owns Organogenesis over time.

Investor Rights

The stipulation for board representation based on ownership percentage illustrates the power early investors wield in shaping corporate direction.

The early ownership structure of Organogenesis Holdings Inc. was significantly influenced by its founders and initial investors. Alan A. Ades and his family have maintained a substantial and long-term ownership interest, with Alan A. Ades serving as a director and former Chair of the Board until April 2023. This continuity is further exemplified by Robert Ades's position on the board of directors. The company's 2018 business combination saw significant early backing from investors like Avista Capital Partners IV, L.P. These PIPE Investors were granted the right to designate a board director, provided they collectively held at least 7.5% of the outstanding Class A common stock. This arrangement highlights how early financial support directly translated into governance influence, shaping the company's trajectory and demonstrating a key aspect of Organogenesis company ownership history. Understanding these early dynamics is crucial for comprehending the current Organogenesis ownership.

Founders and Early Investors

The foundation of Organogenesis Holdings Inc. was built upon the significant involvement of its founders and early financial partners. These initial stakeholders played a crucial role in establishing the company's direction and governance.

• The Ades family, through Alan A. Ades and Robert Ades, represents a core element of the company's ownership and leadership.
• Early investors, such as Avista Capital Partners IV, L.P., provided essential capital and gained influence through board representation rights.
• The 7.5% ownership threshold for board designation by early investors underscores the importance of substantial early capital in shaping corporate control.
• These early relationships and ownership percentages are foundational to understanding who owns Organogenesis and its overall company structure.
• The historical context of Organogenesis company ownership by private equity and founding families is key to its evolution.
• For a deeper understanding of the market this company serves, explore the Target Market of Organogenesis.

Organogenesis SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Organogenesis Holdings Inc. is a publicly traded entity on the Nasdaq Capital Market under the ticker ORGO. Its ownership structure reflects a blend of institutional and individual investors, with significant holdings by specialized investment firms.

The company's ownership is distributed among various entities, with institutional investors holding a notable portion. As of August 18, 2025, with approximately 127 million shares outstanding and a share price of $4.58, the total market capitalization reached around $581.66 million. Individual investors comprise a significant segment of the shareholder base, representing 40.58% of ownership, while institutional investors hold 32.83%. Gary S. Gillheeney, Sr., who serves as President, CEO, and Chair of the Board, directly owns 1.4% of the company's shares, an investment valued at approximately $8.40 million. This breakdown illustrates the diverse nature of Organogenesis company ownership.

Key Organogenesis Investors

Organogenesis has a broad base of investors, with several major institutions holding substantial stakes. Understanding who owns Organogenesis provides insight into its financial backing and strategic direction.

• Soleus Capital Management, L.P. is a significant institutional shareholder.
• Morgan Stanley also holds a considerable number of Organogenesis stock.
• Vanguard Group Inc. and BlackRock, Inc. are among the prominent institutional investors.
• Individual investors collectively represent a substantial portion of Organogenesis company ownership.
• The CEO, Gary S. Gillheeney, Sr., is also a direct shareholder, aligning management interests with those of other Organogenesis investors.

Organogenesis PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The Organogenesis Holdings Inc. board of directors is composed of individuals with diverse backgrounds, including company leadership, major shareholders, and independent experts. Gary S. Gillheeney, Sr. holds key executive roles as President, Chief Executive Officer, and Chair of the Board. Robert Ades represents significant family ownership, while Arthur S. Leibowitz serves as Lead Independent Director.

The voting power within Organogenesis Holdings Inc. is primarily structured around its Class A Common Stock, which operates on a one-share-one-vote principle. However, the Series A Convertible Preferred Stock, issued to Avista Healthcare Partners in November 2024, introduces a distinct voting dynamic. This preferred stock grants voting rights on an as-converted basis, with a limitation of 19.99% on conversion rights until stockholder approval is obtained. This structure provides Avista Healthcare Partners with a significant influence, especially considering their substantial investment and the minimum liquidation preference attached to their preferred stock, underscoring a key aspect of Organogenesis company ownership.

Understanding Organogenesis Ownership and Board Dynamics

The composition of the board and the voting rights associated with different stock classes are crucial for understanding Organogenesis company ownership. These elements influence strategic decisions and the overall direction of the company.

• Board members represent both internal leadership and external investor interests.
• The Series A Convertible Preferred Stock held by Avista Healthcare Partners carries specific voting rights.
• A 19.99% limitation on conversion rights for preferred stock is in place pending stockholder approval.
• The Growth Strategy of Organogenesis is likely shaped by its board and major shareholders.
• Understanding Organogenesis stock is key to grasping its ownership structure.

Organogenesis Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Organogenesis Holdings Inc. has experienced significant shifts in its ownership structure over the past few years, marked by strategic capital infusion and leadership changes. These developments are crucial for understanding the company's current and future trajectory.

The company's ownership landscape is evolving, with a notable private placement of $130 million in Series A Convertible Preferred Stock completed in November 2024 with affiliates of Avista Healthcare Partners. This transaction also involved a privately negotiated repurchase of approximately $23.5 million in Class A common stock from certain directors and their affiliates. In leadership, Gary S. Gillheeney, Sr. assumed the role of Chair of the Board in April 2023, in addition to his ongoing positions as President and CEO. The company's Mission, Vision & Core Values of Organogenesis are supported by these strategic financial and leadership decisions.

Institutional Investor Activity

As of August 2025, Organogenesis has 294 institutional owners. This indicates a growing interest from larger financial entities in the company's stock.

Insider Transactions

In the three months leading up to June 2025, insiders were observed to be purchasing more shares than they sold, suggesting confidence in the company's prospects.

Potential Future Dilution

While shareholders experienced minimal dilution in the past year as of August 2025, increases in equity incentive plans and the potential conversion of preferred stock could lead to future dilution.

Strategic Ownership Influence

The convertible preferred stock from Avista Healthcare Partners, pending stockholder approval for full conversion, represents a significant factor that could alter the company's ownership structure and strategic direction.

Organogenesis Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔